Octapharma study highlights benefits of Wilate

Octapharma has presented clinical data on its von Willebrand factor (VWF)/coagulation factor VIII (FVIII) concentrate Wilate, which demonstrates the treatment's effectiveness against von Willebrand Disease (VWD) and haemophilia B.

At an Octapharma-sponsored symposium at the World Federation of Haemophilia world congress, a number of medical experts gave talks highlighting Wilate's biochemical and pharmacokinetic profile and ability to improve treatment, monitoring and dosing.

One of these studies underlined the effectiveness of the next-generation VWF/FVIII concentrate in aiding haemostatic management of surgical procedures among VWD patients, while another demonstrated its superior performance compared to older products.

Other data presented during the symposium showed that Wilate can help to prevent bleeding among patients undergoing prophylactic treatment.

Dr Olaf Walter, head of Octapharma's haematology business unit, said: "The increased clinical efficacy and safety profiles provided by Wilate … reflect our vision of a more convenient on-demand and prophylactic therapy with minimised thromboembolic risks developed especially for VWD."

The World Federation of Haemophilia also saw Octapharma present data on another FVIII inhibitor treatment, Octanate, highlighting its safety and efficacy.